Acute Effects of Cholecystokinin Tetrapeptide on Brain Stem Auditory Evoked Potentials in Healthy Volunteers

Pharmacopsychiatry

Volumn 36, Issue 5, 2003, Pages 181-186

  Gunnarsson, T ^a   Mahoney, C ^b   Shlik, J ^c   Bradwejn, J ^b   Knott, V ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

Anxiety, panic; Brain stem auditory evoked potentials; CCK 4; Cholecystokinin

Indexed keywords

GASTROINTESTINAL AGENT; PLACEBO; TETRAGASTRIN;

ADOLESCENT; ADULT; AFFECT; ALERTNESS; ANXIETY; ARTICLE; BLOOD PRESSURE; BRAIN STEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; EVOKED AUDITORY RESPONSE; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; MALE; MEMORY; MOOD; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STARTLE REFLEX; SYMPTOM;

ADOLESCENT; ADULT; AFFECT; BLOOD PRESSURE; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GASTROINTESTINAL AGENTS; HEART RATE; HUMANS; MALE; TETRAGASTRIN;

EID: 0242320555     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43047     Document Type: Article

References (55)

1. Abelson JL, Nesse RM. Pentagastrin infusions in patients with panic disorder. I: Symptoms and cardiovascular responses. Biol Psychiatry 1994; 36: 73-83
2. Albus M. Cholecystokinin. Prog Neuro-Psychopharmacol and Biol Psychiatry 1988; 12: S5-21
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.; Fourth Edition ed Washington, D.C: American Psychiatric Association, 1994
4. Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M. The raphe nuclei of the cat brainstem: a topographical atlast of their efferent projections as revealed by autoradiography. Brain Res 1976; 113: 449-486
5. Bourin M, Malinge M, Guitton B. Provocative agents in panic disorder. Therapie 1995; 50: 301-306
6. Bradweyn J, Kosycki D, Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 1990; 35: 83-85
7. Bradwejn J, Koszycki D, Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatry Neurosci 1991; 16: 91-95
8. Bradwejn J, Koszycki D, Payeur R. Cholecystokinin-tetrapeptide: A provocation agent for research in panic disorders?. In Briley M, Files S (eds). New Concepts in anxiety MacMillan Press, London: 1991
9. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991; 7: 603-610
10. Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. In Reeve JR Jr, Solomon TE, Go VL (eds). Cholecystokinin The New York Academy of Sciences, New York, NY: 1994
11. Branchereau R, Champagnat J, Roques B, Denavit-Saubie M. CCK modulates inhibitory synaptic transmission in the solitary complex through CCK B sites. Neuroeport 1992; 3: 909-912
12. Caspary D, Havey D, Faingold C. Effects of microiontophoretically applied glycine and GABA on neuronal response pattern in the cochlear nuclei. Brain Res 1979; 172: 179-185
13. Charney DS, Heninger GR, Jatlow P. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985; 42: 233-243
14. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144: 1030-1036
15. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiat Scand 1992; 86: 273-282
16. Chiappa K. Evoked potentials in clinical medicine. Lippincott - Raven Publishers (3rd Ed). Philadelphia: 1997
17. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998; 44: 1264-1276
18. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994; 15: 731-755
19. Crawley JN. Interactions between cholecystokinin and other neurotransmitter systems. In Bradwejn J, Vasar E (eds). Cholecystokinin and anxiety: from neuron to behavior Springer Verlag, Austin: 1995
20. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989; 46: 511-517
21. Derogatis L, Lipman R, Richels K. The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. In Pichot P (ed). Psychological measurement: modern problems in pharmacopsychiatry Karger, Basel, Switzerland: 1979
22. Don M, Eggermont J. Analysis of the click-evoked brainstem potentials in man using high-pass noise masking. J Accost Soc Am 1978; 63: 1084-1092
23. Epstein CM. The use of brain stem auditory evoked potentials in the evaluation of the central nervous system. Neurol Clin 1998; 6: 771-790
24. Eybalin M, Parnaud C, Geffard M, Pujoi R. Immunoclectron miscroscopy identiifes several types of GABA-contaning efferent synapses in the guinea-pig organ of Corti. Neurosci 1988; 24: 29-38
25. Fex J, Altschuler R, Kachar B, Wenthold R, Zempel J. GABA visualized by immunocytochemistry in the guinea pig cochlea in axons and endings of efferent neurons. Brain Res 1986; 366: 106-117
26. Fitzgerald JD. Pentagastrin as a stimulant of maximal gastric acid response in man. Lancet 1967; 1(7485): 291-295
27. Gorman JM, Liebowitz MR, Fyer AJ, Stein J. A neuroanatomical hypothesis for panic disorder. Am J of Psychiatry 1989; 146: 148-161
28. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14: 244-249
29. Harro J, Vasar E, Koszycki D, Bradwejn J. Cholecystokinin in panic and anxiety disorders. Adv Biol Psychiatry 1995; 1: 235-262
30. Hendry S, Jones E, DeFelipe J, Schmochel D, Brandon C, Emson P. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci 1984; 81: 6526-6530
31. Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 1999; 45: 872-822
32. Knott VJ, Lapierre YD. Effects of lactate-induced panic attacks on brain stem auditory evoked potentials. Neuropsychobiology 1986; 16: 9-14
33. Knott VJ, Bakish D, Barkley J. Brainstem evoked potentials in panic disorder. J Psychiatry and Neurosci 1994; 19: 301-306
34. Levy D, Kimhi R, Barak Y, Demmer M, Harel M, Elizur A. Brainstem auditory evoked potentials of panic disorder pateints. Neuropsychobiology 1996; 33: 164-167
35. Liebowitz MR, Gorman JM, Fyer A, Dillon D, Levitt M, Klein DF. Possible mechanisms for lactate's induction of panic. Am J Psychiatry 1986; 143: 495-502
36. McDonald A, Pearson J. Coexistence of GABA and peptide immunoractivity in non-pyramidal neurons of the basolateral amygdala. Neuroscience Lett 1989; 100: 53-58
37. Noble F, Roques BP. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiology 1999; 58: 349-379
38. Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz M, Hollander E, Tyer A, Jordan E, Gorman J. Diagnostic and substance specificity or carbon dioxide-induced panic. Am J Psychiatry 1993; 150: 250-257
39. Parnaud C, Eybalin M, Geffard M, Pujoi R. Light and electron microscopic localization of GABA-immunostraining in efferent fibres of the organ of Corti. Neurosci Lett Suppl 1986; 26: S284
40. Picton T, Hilliard S, Krausz H, Galambos R. Human auditory evoked potentials. I: Evaluation of components. Electroencephalogy Clin Neurophysio 1974; 36: 179-190
41. Pohl R, Yeragani VK, Balon R, Rainey J, Lycaki H, Ortiz A, Berchou R, Weinberg P. Isoproterenol-induced panic attacks. Biol Psychiatry 1988; 24: 891-902
42. Pyke RE, Greenberg HS. Norepinephrine challenges in panic patients. J Clin Psychopharmacol 1986; 6: 279-285
43. Rehfeld JF, Nielson FC. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In Bradwejn J, Vasar E (eds). Cholecystokinin and anxiety: from neuron to behavior Springer Verlag, Austin: 1995
44. Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy. CNS Drugs 1997; 8: 134-152
45. Shlik J, Koszycki D, Bradwejn J. Decrease in short-term memory ufnction induced by CCK-4 in healthy volunteers. Peptides 1998; 19: 969-975
46. Shlik J, Zhou Y, Koszycki D, Vaccarino FJ, Bradwejn J. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol 1999; 13: 385-390
47. Somogyi L, Hodgson A, Smith A, Nunzi M, Gorio A, Wu J. Different populations of GABA-ergic neurons in the visual cortex and hippocampus of CAT contain somatostalin or cholecystokinin-immunoreactive material. J Neursci 1984; 4: 2590-2603
48. Thompson G, Cortez A, Lam D. Localization of GABA immunoreactivity in the auditory brainstem of guinea pigs. Brain Res 1985; 339: 119-122
49. van Megan HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 1994; 114: 449-455
50. van Megan HJGM, Westenberg HGM, Den Boer JA, Kahn RS. The panic-inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients with panic disorder. Eur Neuropsychopharmacol 1996; 6: 187-194
51. Vetter D, Adams J, Mirgiaini E. A dual efferent GABAergic projection to the rat cochlea. Soc Neurosci Ab 1986; 12: 979
52. Westerberg B, Roberson J, Stach B. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus. Am J Otol 1996; 17: 896-903
53. Yeudall L, Schopflocher D, Sussman P, Barabash W, Warneke L, Gill D, Oho W, Howarth B, Tormanson P. Panic attack syndrome with and without agoraphobia: neuropsychological and evoked potential correlates. In Flor-Henry P, Gruzedier J (eds). Laterality and psychopathology, Elsevier, New York: 1983
54. Gormon J, Kent J, Sullivan G, Coplan J. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157: 493-505
55. Tsutsumi T, Akiyoshi J, Hikichi T, Kiyota A, Kohno Y, Katsurasi S, Yamamoto Y, Isogawa K, Nagayama H. Suppression of conditional fear by administration of CCKB receptor antisense oligodeoxynucleotide into the lateral ventricle. Pharmacopsychiatry 2001; 6: 232-237